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Abstract
Objective—Accumulating preclinical and epidemiologic evidence has emerged to suggest that
modulation of cytochrome P450 (CYP)-mediated eicosanoid metabolism may be a viable vascular
protective therapeutic strategy for the secondary prevention of coronary artery disease (CAD). The
functional relationship between CYP-derived eicosanoid metabolite levels and vascular
dysfunction in humans with established CAD, however, has not been evaluated. Therefore, we
characterized the relationship between inter-individual variation in soluble epoxide hydrolase
(sEH) and CYP ω-hydroxylase metabolism and established vascular function phenotypes
predictive of prognosis in a cohort of patients with atherosclerotic cardiovascular disease.
Methods—Plasma epoxyeicosatrienoic acid (EET), dihydroxyeicosatrienoic acid (DHET), and
20-hydroxyeicosatetraenoic acid (20-HETE) levels were quantified by HPLC-MS/MS in 106
patients with stable, angiographically-confirmed CAD. Relationships between biomarkers of
CYP-mediated eicosanoid metabolism and vascular function phenotypes were evaluated by
Pearson’s correlation.
Results—A significant inverse association was observed between 20-HETE levels (a biomarker
of CYP ω-hydroxylase metabolism) and brachial artery flow-mediated dilation (r = −0.255, p =
0.010). An inverse association was also observed between 14,15-EET:DHET ratios (a biomarker
of sEH metabolism) and both monocyte chemoattractant protein-1 levels (r = −0.252, p = 0.009)
and a consolidated cellular adhesion molecule ‘score’ reflecting the levels of E-selectin and P-
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selectin (r = −0.216, p = 0.027). No associations with C-reactive protein or epithelial neutrophil-
activating protein-78 levels were observed.
Conclusions—Collectively, these findings demonstrate that enhanced CYP ω-hydroxylase and
sEH metabolic function are associated with more advanced endothelial dysfunction and vascular
inflammation, respectively, in patients with established atherosclerotic cardiovascular disease.
These findings lay the foundation for future clinical research in this area.
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1. Introduction
Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide
and despite recent advances, novel therapies are needed to further improve outcomes.
Inflammation and impaired arterial vasodilation (endothelial dysfunction) are key drivers of
the pathogenesis and progression of CAD in preclinical models and humans [1]. It is well-
established that elevated circulating biomarkers of systemic (C-reactive protein) [2] and
vascular (chemokines, cellular adhesion molecules [CAMs]) [3,4] inflammation and
impaired physiologic measures of endothelial function (brachial artery flow-mediated
dilation [FMD]) [5] are predictive of poor prognosis in patients with established CAD.
Therefore, CAD patients with persistent vascular inflammation and/or endothelial
dysfunction, despite treatment with current standards of care, may be candidates for adjunct
therapeutic strategies specifically designed to improve vascular function. Identification of
the key pathways that regulate these phenotypes in humans, however, is essential to
facilitate the development of targeted therapies for these high-risk subsets of the population.
Accumulating preclinical and epidemiologic evidence has emerged to suggest that
modulation of cytochrome P450 (CYP)-mediated eicosanoid metabolism may be a viable
clinical therapeutic strategy for the management of cardiovascular disease [6,7]. The CYP2J
and CYP2C epoxygenases metabolize arachidonic acid to four epoxyeicosatrienoic acid
(EET) regioisomers (5,6-, 8,9-, 11,12-, and 14,15-EET), which possess potent vasodilatory
and anti-inflammatory effects. The EETs, however, are rapidly metabolized to less active
dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH). In parallel,
CYP4F and CYP4A ω-hydroxylases generate 20-hydroxyeicosatetraenoic acid (20-HETE),
which exhibits potent vasoconstrictive and pro-inflammatory effects. Inhibition of sEH
mediated EET hydrolysis and CYP ω-hydroxylase mediated 20-HETE biosynthesis each
elicit potent protective effects in preclinical models of endothelial dysfunction and
hypertension, nuclear factor (NF)-κB dependent vascular inflammation, atherosclerosis, and
myocardial ischemia-reperfusion injury [6,8–13]. In humans, genetic epidemiology studies
have shown that functional polymorphisms in CYP epoxygenases (CYP2J2 and CYP2C8),
sEH (EPHX2), and CYP ω-hydroxylases (CYP4F2 and CYP4A11) are associated with the
development of cardiovascular disease [14–16].
Furthermore, we recently reported that patients with established atherosclerotic
cardiovascular disease exhibit higher plasma EET levels and higher 14,15-EET:DHET ratios
compared to healthy individuals at low risk for cardiovascular disease [17]. Conversely, no
significant differences in 20-HETE levels were observed. Due to the vascular protective
effects of EETs in preclinical models, these data suggest that the presence of cardiovascular
disease may lead to a compensatory suppression of sEH-mediated EET hydrolysis in
humans. Importantly, pharmacologic inhibitors of sEH [18] and CYP ω-hydroxylase
metabolism [19] are currently in development. Although these novel therapies are
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hypothesized to improve prognosis in CAD patients by eliciting protective effects in the
vasculature via increasing EET and decreasing 20-HETE levels, respectively, it remains
unknown whether CAD patients with dysregulated CYP-mediated eicosanoid metabolism
exhibit more advanced vascular dysfunction. A more thorough understanding of the role of
CYP-derived EETs and 20-HETE in the regulation of vascular function in patients with
established CAD offers enormous potential to identify subsets of the population with
dysregulated eicosanoid metabolism (i.e., low EET and/or high 20-HETE levels) who may
be most likely to derive benefit from these novel therapies in development.
Therefore, the primary objective of this study was to characterize the relationship between
inter-individual variation in CYP-mediated eicosanoid metabolism and key vascular
function phenotypes in patients with stable atherosclerotic cardiovascular disease, and
determine whether the subset of individuals with enhanced sEH and CYP ω-hydroxylase
metabolic function exhibit endothelial dysfunction and advanced inflammation.
2. Methods
For an expanded description of the methods, please see the Online Supplement.
2.1. Study population
A cohort of 106 individuals with established and stable CAD, defined as ≥50% stenosis in
one or more major epicardial coronary arteries by coronary angiography, were identified in
the University of North Carolina (UNC) Cardiac Catheterization Laboratory, as described
[17,20]. Eligible participants provided written informed consent and returned 65 ± 35 days
after their catheterization for a single morning study visit and blood sample collection after
fasting overnight and withholding their morning medications. All participants were
clinically stable and chest pain free at the time of their study visit. The study protocol was
approved by the UNC Biomedical Institutional Review Board.
2.2. Evaluation of endothelial function
Endothelium-dependent vasodilation was assessed by brachial artery FMD, as previously
described [20]. Brachial artery diameter was assessed at baseline and following reactive
hyperemia, and FMD was calculated as the peak percent change in diameter from baseline.
2.3. Quantification of inflammatory biomarkers
High sensitivity C-reactive protein (hs-CRP) was quantified in fresh serum using the
VITROS® 5600 Chemistry System (Ortho-Clinical Diagnostics, Inc., Rochester, NY).
Plasma CAM (E-selectin and P-selectin), neutrophil chemokine (epithelial neutrophil-
activating protein [ENA]-78) and monocyte chemokine (monocyte chemoattractant protein
[MCP]-1) concentrations were quantified using Multi-Analyte Profiling Kits (R&D
Systems, Minneapolis, MN).
2.4. Quantification of plasma eicosanoids
Cytochrome P450-derived eicosanoid metabolite concentrations were quantified in plasma
after solid phase extraction by high-performance liquid chromatography followed by tandem
mass spectrometry (HPLC–MS/MS) as previously described [17]. Plasma 20-HETE levels
(the bioactive metabolite of the CYP ω-hydroxylase enzymes) were utilized as a biomarker
of CYP ω-hydroxylase pathway function [17]. The 14,15-EET:DHET ratio (a sensitive in
vivo biomarker of sEH metabolic function) [8,15] and the sum of EETs (the bioactive
metabolites of CYP epoxygenase enzymes) were utilized as biomarkers of CYP
epoxygenase pathway function [17] (Supplemental Fig. 1).
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Data are presented as mean ± standard deviation or median (interquartile range) unless
otherwise indicated. Since a significant correlation was observed between E-selectin and P-
selectin (r = 0.599, p < 0.001), a consolidated ‘CAM score’ phenotype was calculated in
each individual. No significant correlations were observed among the final five biomarkers
of vascular function (Supplemental Table 1), indicating these biomarkers represent five
distinct phenotypes.
For the primary analysis, associations between circulating biomarkers of CYP-mediated
eicosanoid metabolism (20-HETE, 14,15-EET:DHET ratio, sum EETs) and the five
phenotypic indices of vascular function (FMD, CAM score, MCP-1, ENA-78, hs-CRP) were
evaluated by Pearson’s correlation. A secondary analysis was conducted using a model that
adjusted for potential demographic (age, race, gender) and clinical (smoking status, diabetes,
obesity, multivessel disease, hypertension, renin–angiotensin system inhibitor use, time
post-catheterization) confounders [17]. In order to further assess the eicosanoid–vascular
function relationships, vascular phenotypes were compared across eicosanoid metabolism
tertiles by analysis of variance (ANOVA) and a post-hoc Student Newman– Keuls test. To
minimize the impact of the multiple statistical tests required for this analysis, a false
discovery rate (FDR) q-value was calculated for each comparison in our primary analysis.
Only q-values for statistically significant findings (p < 0.05) are presented. All statistical
analyses were performed using SAS Version 9.2 (SAS Institute, Cary, NC).
3. Results
3.1. Study population
The population characteristics are shown in Table 1. The majority of patients had advanced
CAD, with 66% exhibiting multi-vessel disease at their index catheterization, and
comorbidities including hypertension (81%), obesity (54%), and diabetes (24%). Medication
utilization and revascularization rates were consistent with current clinical practice
guidelines.
3.2. CYP ω-hydroxylase pathway
The relationships between inter-individual variation in CYP-derived eicosanoid levels and
vascular function are provided in Table 2. Plasma 20-HETE levels were significantly
associated with endothelial dysfunction, such that patients with higher levels of 20-HETE
had lower FMD (Fig. 1A, r = −0.255, p = 0.010, q = 0.048). A significant inverse
association was also observed in the adjusted model (r = −0.223, p = 0.033). Similarly, a
stepwise trend of lower FMD was observed across increasing tertiles of 20-HETE (Fig. 1B,
p for trend = 0.080); however, statistically significant differences were not observed
between each tertile. Circulating 20-HETE levels were not associated with either
nitroglycerin-mediated dilation (r = −0.068, p = 0.495) or baseline brachial artery diameter
(r = 0.074, p = 0.455), indicating that the mechanism underlying the association between 20-
HETE and FMD is endothelium-dependent and is not explained by differences in arterial
size.
A positive relationship between 20-HETE levels and the CAM score was also observed
(unadjusted: r = 0.191, p = 0.051; adjusted model: r = 0.222, p = 0.031); however, the
association was not statistically significant in the primary analysis. In contrast, no
association was observed between 20-HETE and either hs-CRP or chemokine levels (Table
2). Similar relationships between 20-HETE levels and each vascular function phenotype
were observed after adjusting for or stratifying by aspirin, clopidogrel, beta-blocker, or statin
use (data not shown).
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3.3. CYP epoxygenase pathway
In contrast to the observed relationship between 20-HETE and endothelial function, no
association was observed between FMD and either 14,15-EET:DHET ratios or sum EETs
(Table 2). Lower 14,15-EET:DHET ratios (indicative of higher sEH metabolic function)
were, however, significantly associated with higher circulating levels of MCP-1 (Fig. 2A, r
= −0.252, p = 0.009, q = 0.048). This association was also significant in the adjusted model
(r = −0.260, p = 0.011), and across tertiles (Fig. 2B). A significant inverse correlation was
also observed between MCP-1 levels and both the sum EET:DHET ratio (r =−0.245, p =
0.012) and 12,13-epoxyoctadecenoic acid (EpOME):dihydroxyoctadecenoic acid (DHOME)
ratio (r = −0.201, p = 0.040). In addition, lower 14,15-EET:DHET ratios were associated
with higher CAM scores (Fig. 2C, r = −0.216, p = 0.027, q = 0.101), such that those in the
lowest tertile had a significantly higher CAM score compared to tertiles 2 and 3 (Fig. 2D).
The inverse relationship between CAM score and 14,15-EET:DHET ratio, however, was not
statistically significant in the adjusted model (r = −0.190, p = 0.065). Similar results were
observed with the sum EET:DHET ratio and 12,13-EpOME:DHOME ratio (data not
shown).
Consistent with the relationship observed with 14,15-EET:DHET ratios, lower sum EET
levels were associated with higher MCP-1 levels (Fig. 3A, r = −0.283, p = 0.003, q = 0.045).
A significant inverse association was also observed in the adjusted model (r = −0.243, p =
0.017). Furthermore, those with sum EET levels in the lowest two tertiles exhibited
significantly higher MCP-1 levels compared to those in the highest tertile (Fig. 3B). When
analyzed separately, a significant inverse relationship was observed between MCP-1 and
both 8,9-EET (r = −0.244, p = 0.012) and 14,15-EET (r = −0.284, p = 0.003) levels. No
association was observed between sum EETs or 14,15-EET:DHET ratio and either hs-CRP
or ENA-78 levels (Table 2). Similar relationships between both 14,15-EET:DHET ratio and
sum EETs and each vascular function phenotype were observed after adjusting for or
stratifying by aspirin, clopidogrel, beta-blocker, or statin use (data not shown).
4. Discussion
Preclinical and genetic epidemiologic studies suggest that increasing CYP-derived EETs
and/or decreasing 20-HETE levels may have utility as a vascular protective therapeutic
strategy in patients with cardiovascular disease. The functional relationship between CYP-
mediated eicosanoid metabolism and vascular dysfunction in humans with established
cardiovascular disease, however, has not been studied to date. This study demonstrated that
higher 20-HETE levels were associated with lower brachial artery FMD and higher CAM
levels and lower 14,15-EET:DHET ratios were associated with elevated MCP-1 and CAM
levels in a population of patients with stable CAD. These findings are consistent with the
vascular effects of 20-HETE and EETs in preclinical models, and suggest that enhanced
CYP ω-hydroxylase and sEH metabolic function predispose stable CAD patients to more
advanced endothelial dysfunction and vascular inflammation, respectively.
It is well-established that biomarkers of vascular function are associated with prognosis in
patients with established CAD [1]. For example, persistently elevated circulating levels of
hs-CRP, CAMs and MCP-1, or genetic predisposition to higher ENA-78 levels, have each
been associated with poorer survival in patients with established CAD [2–4,21]. Similarly,
CAD patients with persistently impaired FMD despite optimized therapy have a higher risk
of cardiovascular events, suggesting that adjunct therapies that improve FMD may
subsequently improve prognosis [5]. Identification of key regulators of these distinct
vascular phenotypes predictive of prognosis offers enormous potential to facilitate the
development of targeted therapies designed to improve vascular function and prognosis in
high-risk subsets of the population.
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The observed inverse association between circulating 20-HETE levels and brachial artery
FMD is consistent with preclinical studies in which 20-HETE directly induces reactive
oxygen species (ROS) production and endothelial nitric oxide synthase uncoupling, reduces
NO availability, and impairs endothelial-dependent vasodilation [9]. An inverse association
between urinary excretion of 20-HETE, which is reflective of renal 20-HETE biosynthesis
[13], and FMD has previously been reported in humans without known CAD [22]. Our
findings with circulating 20-HETE are consistent with this report; however, we are the first
to demonstrate an association between 20-HETE and FMD in humans with established
CAD. We also observed a positive relationship between plasma 20-HETE levels and
circulating CAMs that is consistent with preclinical studies demonstrating that 20-HETE
directly induces CAM expression in endothelial cells through activation of NF-κB [23]. In
our previous case–control analysis, we did not observe a significant difference in 20-HETE
levels in stable CAD patients compared to healthy individuals; however, CAD patients who
were not treated with a renin–angiotensin system inhibitor exhibited modestly higher 20-
HETE levels compared to healthy individuals [17]. Our current findings suggest that despite
being treated with current standard of care therapies (including renin–angiotensin system
inhibitors), CAD patients with the highest 20-HETE levels may be predisposed to more
advanced endothelial dysfunction and vascular inflammation, and therapeutic strategies that
directly decrease 20-HETE biosynthesis may improve vascular function in this high-risk
population.
Consistent with a series of preclinical studies and our hypothesis, we are also the first to
report that lower EET:DHET ratios, a biomarker of enhanced sEH metabolic function, were
associated with higher plasma MCP-1 and CAM levels. Indeed, EETs exert potent anti-
inflammatory effects in the vasculature in preclinical models via attenuation of NF-κB
activation and chemokine and CAM expression [10,11], and these effects are potentiated via
inhibition of sEH [6]. These data are consistent with a recent report demonstrating that
CYP2J2 and CYP2C8 are expressed in human monocytes, and CYP epoxygenase metabolic
function attenuates monocyte/macrophage activation [24]. In addition, a recent study in mice
demonstrated that sEH activity in bone marrow-derived cells, the primary site of chemokine
biosynthesis, is a key regulator of plasma epoxide:diol ratios [25]. We previously reported
that plasma epoxide:diol ratios were significantly higher in patients with established CAD
compared to healthy individuals at low risk for cardiovascular disease [17]. Due to the
aforementioned vascular protective effects of EETs, these data suggest that the presence of
cardiovascular disease may lead to a compensatory suppression of sEH metabolic function
and higher EET levels in humans. However, our current findings suggest that, in spite of a
potential compensatory increase in EET levels overall, the subset of CAD patients with the
highest sEH metabolic function may be predisposed to more advanced vascular
inflammation. Consequently, therapeutic strategies that further increase EET levels, most
notably sEH inhibitors, may represent an effective secondary prevention strategy by
attenuating vascular inflammation and improving prognosis in this high-risk population.
In contrast, we did not observe an association between 14,15-EET:DHET ratio and FMD
which is surprising given the known vasodilatory properties of EETs in preclinical models
and our previous finding that EPHX2 genotype is associated with vasodilator responses in
healthy individuals [26]. In addition to the different populations, it should be noted that
brachial artery FMD (an index of NO bioavailability and conduit arterial function) was
evaluated in the current study while bradkyinin-induced changes in forearm blood flow (a
phenotype more reflective of microvascular function) was evaluated in the previous study.
Although these contrasting results may not be surprising given the more prominent role of
EETs in the regulation of microvascular compared to macrovascular tone in preclinical
models [7], it is important to note that our current findings are consistent with previous
studies demonstrating that CYP epoxygenase inhibition does not impair endothelium-
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dependent vasodilator responses in CAD patients in vivo [27], or in isolated coronary
arterioles from patients undergoing cardiac surgery [28], due to the presence of enhanced
oxidative stress. Collectively, these data suggest that the vasodilatory effects of CYP-
derived EETs may be overwhelmed and masked by the presence of ROS in populations with
underlying vascular inflammation and remodeling, such as atherosclerotic cardiovascular
disease. This hypothesis requires rigorous investigation in prospective interventional studies.
No associations were observed between biomarkers of CYP-mediated eicosanoid
metabolism and hs-CRP. While chemokines and CAMs mediate inflammation in the
vasculature, hs-CRP is an acute-phase reactant released from the liver indicative of systemic
inflammation [29]. Consequently, our findings indicate that CYP-derived eicosanoids may
be important in the regulation of vascular, but not hepatic or systemic, inflammation in
humans. This is consistent with previous observations in preclinical models demonstrating
that the hepatic inflammatory response to endotoxin is not attenuated in Ephx2 knockout
mice [30]. Furthermore, no relationship between CYP-mediated eicosanoid metabolism and
the neutrophil chemokine ENA-78 was observed. We have reported that genetic potentiation
of the CYP epoxygenase pathway attenuates induction of ENA-78 expression and neutrophil
infiltration in mice [11]. In contrast, CYP epoxygenase enzymes are not expressed in human
polymorphonuclear cells [24], suggesting the presence of species differences in the
contribution of CYP-derived eicosanoids to the regulation of neutrophil activation.
Our analysis has limitations that must be acknowledged. First, although the observed
associations were consistent with prior preclinical studies, the cross-sectional design does
not allow us to establish a cause-and-effect relationship between eicosanoid metabolism and
vascular function. Second, our analysis included multiple statistical comparisons and was
limited by its relatively small sample size. To account for the possibility of false-positive
findings, we calculated an FDR q-value for each comparison. All statistically significant
associations had an FDR of 10% or less, and were in directions consistent with prior
preclinical evidence, giving us a higher level of confidence in our results. Furthermore, at α
= 0.05, there was greater than 80% power to detect an r2 of 0.07 for each eicosanoid
metabolism–vascular phenotype relationship, which is similar in magnitude to the well-
established and clinically relevant association observed between body mass index and hs-
CRP in previous studies [29]. This demonstrates that we had ample statistical power to
detect biologically meaningful and clinically relevant relationships in the current study.
Importantly, validation of the observed relationships in an independent cohort will
ultimately be necessary. Lastly, the population under investigation had established
atherosclerotic cardiovascular disease and thus was being treated according to current
clinical practice guidelines, including multiple medications that impact vascular function
(i.e., statins, low-dose aspirin, clopidogrel, beta-blockers). Moreover, the impact of these
medications (most notably aspirin which modifies prostanoid levels) on CYP-mediated
eicosanoid metabolism has not been rigorously evaluated in preclinical models or humans,
and thus remains unknown. Therefore, we cannot elucidate whether the observed
relationships were modified by medication use. Although our adjusted and stratified
analyses showed similar associations between biomarkers of CYP-mediated eicosanoid
metabolism and vascular function phenotypes irrespective of medication use, evaluation of
the direct impact of medication use on EET and 20-HETE levels, as well as the modifying
effect of medication use on the observed eicosanoid–vascular function relationships, is
beyond the scope of the current investigation and requires further study. Importantly, since
pharmacologic agents in development that increase EETs (sEH inhibitors) or decrease 20-
HETE (CYP ω-hydroxylase inhibitors) would most likely be used as a secondary prevention
strategy for CAD, in addition to these standard of care medications, our study was designed
to specifically characterize associations between biomarkers of CYP-mediated eicosanoid
metabolism and vascular function in a population of stable, appropriately treated patients
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with established CAD. These data lay a foundation for the rational design of subsequent
studies that aim to directly evaluate the effects of novel therapies that decrease 20-HETE
and increase EET levels on vascular function in patients with established CAD.
5. Conclusions
This cross-sectional analysis demonstrates that higher circulating 20-HETE levels are
associated with lower brachial artery FMD and higher CAMs and lower 14,15-EET:DHET
ratios are associated with elevated MCP-1 and CAM levels in a population of patients with
stable CAD. These findings suggest that enhanced CYP ω-hydroxylase and sEH metabolic
function may predispose patients with established atherosclerotic cardiovascular disease to
more advanced endothelial dysfunction and vascular inflammation despite current standards
of care. These findings lay a critical foundation for future clinical research in this area,
including the rational design of interventional proof-of-concept studies that seek to define
the vascular protective effects and safety of decreasing CYP-mediated 20-HETE
biosynthesis and/or decreasing sEH-mediated EET hydrolysis in patients with established
CAD.
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Association between 20-HETE levels and FMD. (A) The correlation between 20-HETE and
FMD is displayed. (B) The distribution of FMD across 20-HETE tertiles is displayed using
box plots (tertile 1: 0.40–1.29 ng/mL, tertile 2: 1.30–1.85 ng/mL, tertile 3: 1.86–6.97 ng/
mL). The horizontal line within the box represents the median, the edges of the box
represent the 25th and 75th percentiles, and the error bars represent the 10th and 90th
percentiles. The ANOVA p-value for the trend is provided.
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Association between 14,15-EET:DHET ratios and biomarkers of vascular inflammation. The
correlation between 14,15-EET:DHET ratio and (A) MCP-1 and (C) CAM score is
displayed. The distribution of (B) MCP-1 and (D) CAM score across 14,15-EET:DHET
ratio tertiles is displayed using box plots (tertile 1: 0.040–0189 ng/mL, tertile 2: 0.190–0.541
ng/mL, tertile 3: 0.542–1.82 ng/mL). The ANOVA p-value for the trend is provided. *p <
0.05 versus tertile 3. †p < 0.05 versus tertile 2.
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Association between sum EETs and MCP-1 levels. (A) The correlation between sum EETs
and MCP-1 is displayed. (B) The distribution of MCP-1 across sum EETs tertiles is
displayed using box plots (tertile 1: 0.086–0.251 ng/mL, tertile 2: 0.252–0.375 ng/mL, tertile
3 0.376–1.26 ng/mL). The ANOVA p-value for the trend is provided. *p < 0.05 versus
tertile 3.
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Age (years) 58 ± 10
Female (%) 35 (33%)
African–American (%) 18 (17%)
Body mass index (kg/m2) 30 ± 6
Obese (BMI ≥ 30 kg/m2; %) 57 (54%)
Current smoker (%) 23 (22%)
Diabetes (%) 25 (24%)
Hypertension (%) 86 (81%)
Previous myocardial infarction 39 (37%)
Multivessel disease 70 (66%)
Recent revascularization procedurea 70 (66%)
Systolic blood pressure (mmHg) 136 ± 17
Diastolic blood pressure (mmHg) 80 ± 10
Total cholesterol (mmol/L) 4.04 (1.32)
LDL cholesterol (mmol/L) 2.20 (0.96)
HDL cholesterol (mmol/L) 1.22 (0.41)
Triglycerides (mmol/L) 1.11 (0.84)
ACE inhibitor or ARB (%) 66 (62%)
Beta-blocker (%) 89 (84%)
Statin (%) 99 (93%)
Aspirin (%) 103 (97%)
Clopidogrel (%) 83 (78%)
Data presented as mean ± standard deviation, median (interquartile range) or count (proportion).
ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, HDL = high density lipoprotein, LDL = low density lipoprotein.
a
59/106 underwent a percutaneous coronary intervention and 11/106 underwent a coronary artery bypass grafting procedure between screening and
the study visit.
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